Green tea compound helps siRNA slip inside cells
Posted: 19 September 2018 | Drug Target Review | No comments yet
Researchers have found a surprising use for EGCG: sneaking therapeutic RNAs into cells…


Drinking green tea has been linked to health benefits ranging from cardiovascular disease prevention to weight loss. Although many of these claims still need to be verified in the clinic, an antioxidant in green tea called epigallocatechin gallate (EGCG) appears to have beneficial effects in cells and animals. Now, researchers have found a surprising use for EGCG: sneaking therapeutic RNAs into cells.
Small interfering RNAs (siRNAs) have great therapeutic potential because they can dial down the expression of disease-related genes. However, getting siRNAs into cells where they can do their job has been challenging. Being relatively large and negatively charged, siRNAs cannot easily cross the cell membrane, and they are susceptible to degradation by RNA-chomping enzymes. To overcome these problems, some researchers have tried coating siRNAs with various polymers. However, most small polymers can’t shuttle siRNAs into cells, whereas larger polymers can be effective but are generally toxic. Yiyun Cheng and colleagues wondered if they could use EGCG, which is known to bind strongly to RNA, in combination with a small polymer to form nanoparticles that safely deliver siRNA into cells.
The team made their nanoparticles by first combining EGCG and siRNA, which self-assembled into a negatively charged core. Then, the researchers coated this core with a shell consisting of a small, positively charged polymer. These nanoparticles efficiently knocked down the expression of several target genes in cultured cells, showing that the particles could cross the cell membrane. Next, the researchers tested the nanoparticles in a mouse model of intestinal injury, using a siRNA that targeted a pro-inflammatory enzyme. The nanoparticles improved symptoms such as weight loss, shortening of the colon and intestinal inflammation. In addition to the gene-silencing effects of the siRNA, EGCG could contribute to the nanoparticles’ effectiveness through its antioxidant and anti-inflammatory properties, the researchers say.
Automation now plays a central role in discovery. From self-driving laboratories to real-time bioprocessing
This report explores how data-driven systems improve reproducibility, speed decisions and make scale achievable across research and development.
Inside the report:
- Advance discovery through miniaturised, high-throughput and animal-free systems
- Integrate AI, robotics and analytics to speed decision-making
- Streamline cell therapy and bioprocess QC for scale and compliance
- And more!
This report unlocks perspectives that show how automation is changing the scale and quality of discovery. The result is faster insight, stronger data and better science – access your free copy today
They report their results in ACS Central Science.
Related topics
Enzymes, Research & Development, RNAs, Screening, Small molecule, Therapeutics
Related people
Yiyun Cheng







